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T he term Polycomb (Pc) initially referred to a Drosophila mutant that displayed improper body segmentation 1 . It was suggested that Polycomb encodes a negative regulator of the homeotic genes that are required for segmentation 2 . The Polycomb group (PcG) now defines a set of genes characterized by mutations that result in similar phenotypes to those of Polycomb. The crucial role of PcG proteins during development is highlighted by early embryonic lethality in mice after the deletion of genes encoding some of these proteins (Eed, Ezh2 (also known as Enx-1), Suz12 and Ring1B (Rnf2)). The antagonistic activities of the PcG and the trithorax families of proteins culminate in the maintenance, throughout development and adulthood, of the appropriate patterns of homeotic gene expression in a spatially defined manner 3 . PcG proteins are found in several families of multiprotein complexes, including the Polycomb repressive complexes PRC1 and PRC2 (Fig. 1) . Two other PcG complexes were characterized in Drosophila, PHO-repressive complex (PhoRC) and Polycomb repressive deubiquitinase (PR-DUB), and their components have orthologues in mammals; however, the conservation of their functions has not yet been addressed [4] [5] [6] . Polycomb-mediated gene silencing is thought to rely mostly on the regulation of chromatin structure, in part through post-translational modification (PTM) of histones. Hence, the PRC2 complex is responsible for the methylation (di-and tri-) of Lys 27 of histone H3 (H3K27me2/3) 3, 6 through its enzymatic subunits EZH1 and EZH2, whereas the PRC1 complex monoubiquitylates Lys 119 of histone H2A (H2AK119ub) via the ubiquitin ligases RING1A and RING1B (Fig. 1 ). In addition, some PRC1 complexes can regulate gene expression by compacting chromatin in a manner independent of enzymatic activity 7 . The PRC1 component Pc (known as CBX in mammals) binds specifically to the product of PRC2 catalysis, H3K27me3, leading to the hypothesis that PRC1 functions downstream of PRC2. Although this premise is still cited in the literature, its operational status is equivocal as there are genes targeted by PRC2 that lack H2AK119ub 8 and genes targeted by PRC1 in the absence of PRC2 (refs 9, 10) . Nonetheless, PRC2 and PRC1 are often both required to maintain gene repression.
Owing to the pivotal role of PRC2 in the coordination of PcG protein function, the still partial characterization of PRC1 and PRC1-like complexes in mammals, and the existence of up-to-date reviews on PRC1 (refs 3, 6) , this Review focuses primarily on mammalian PRC2. After considering PRC2 in terms of evolution, we evaluate the newly appreciated, variable composition of PRC2 and describe the function of its catalytic product and its localization. Finally, we discuss the biological roles of PRC2, and propose a model for its recruitment to target genes that involves non-coding RNA (ncRNA).
Evolution of PRC2
The core PRC2 complex, which is conserved from Drosophila to mammals, comprises four components: EZH1/2, SUZ12, EED and RbAp46/48 (also known as RBBP7/4). The composition of PRC1 complexes is more variable, with only two core common components -RING1A/B together with BMI1, MEL18 (PCGF2) or NSPC1 (PCGF1) 6, 11 ( Fig. 1) . The presence of PRC2 in various unicellular eukaryotes led to the suggestion that it existed in the last common unicellular ancestor, but it was lost at times during evolution as exemplified by the cases of Schizosaccharomyces pombe and Saccharomyces cerevisiae, in which PRC2 is absent 12 . Notably, the PRC2 components, in contrast to those of PRC1, underwent little duplication in mammals, with vertebrates containing two copies of enhancer of zeste homologue, EZH1 and EZH2 (ref. 12) . Drosophila has two copies of the EED homologue, ESC and ESCL. Although ESC and ESCL are interchangeable 13 , the same might not be true for EZH1 and EZH2, which have different expression patterns. EZH1 is present in both dividing and differentiated cells, whereas EZH2 is found only in actively dividing cells. Also, PRC2 complexes containing EZH1 (PRC2-EZH1) in lieu of EZH2 have low methyltransferase activity compared with PRC2-EZH2 (ref. 14) . This indicates that PRC2-EZH2 establishes cellular H3K27me2/3 levels through its EZH2-mediated methyltransferase activity, and that PRC2-EZH1 restores H3K27me2/3 that could have been lost after histone exchange or through demethylase activity. Moreover, PRC2-EZH1 and -EZH2 have distinct chromatin-binding properties, as illustrated by the specific chromatin-compaction property of PRC2-EZH1 (ref. 14) .
In contrast to mammals, PRC2 evolved towards a greater complexity in plants, with species such as Arabidopsis thaliana having up to 12 homologues of PRC2 components 15 . A homologue of the mammalian and S. pombe heterochromatin protein 1 (HP1) that binds to H3K9me3 also exists in plants and is denoted LHP1. LHP1 binds to H3K27me3 and interacts with the RING1 homologues AtRING1A and AtRING1B, suggesting the existence of a PRC1-like complex The Polycomb complex PRC2 and its mark in life in plants 15 . Whereas EZH1 and EZH2 target the same genes and are expected to contribute to the same silencing pathway 16 , the plant PRC2 complexes were reported to have distinct functions 15 . On the basis of these criteria, we speculate that PRC2 evolved from a function that was partially redundant with gene silencing through the H3K9me3 pathway, gaining a more specific role as multicellular organisms acquired specific cell lineages.
PRC2 comprises more than four components
The first PRC2 purifications led to the identification of the four components that are required for its enzymatic activity in vitro. It was recently shown that PRC2 contains several other polypeptides (Fig. 1 ) -AEBP2, PCLs and JARID2 -the functions of which are described below. Of note, other proteins transiently interact with PRC2 (for example, DNMTs, HDAC1 and SIRT1), but their effect on PRC2 function is unclear, and as such, they are not discussed further here.
AEBP2 is a zinc-finger protein that was identified as part of the PRC2 complex. It interacts with several PRC2 components to enhance its enzymatic activity 17 , and co-localizes with PRC2 at some target genes 18 . AEBP2 was postulated to bind DNA with an apparently relaxed specificity 18 . PCL1, PCL2 and PCL3 (also known as PHF1, MTF2 and PHF19, respectively) are the three mammalian orthologues of Drosophila Polycomblike (PCL). They share the same protein motifs: a tudor domain, two plant homeodomain (PHD) finger proteins, a PCL extended domain and a carboxy-terminal domain tail 19 ( Fig. 1) . PCL proteins interact with PRC2 through EZH2, and to some extent through SUZ12 and the histone chaperones RbAp46 and RbAp48 (ref. 20) . Genome-wide studies showed that PCL2 co-occupied PRC2 target genes 21, 22 . Various functions have been attributed to PCLs, from the regulation of PRC2 enzymatic activity 20, 23 to the gene recruitment of PRC2 (refs 21, 24) . Mammalian PCLs are expressed in a tissue-specific manner 21 , and this redundancy could explain apparent discrepancies between studies. The phenotypes associated with PCL mutation in Drosophila and Xenopus, and the colocalization and interaction of PCLs and PRC2, point to PCL proteins having a crucial role in PRC2 function. Understanding the underlying molecular mechanisms will probably require a detailed understanding of how PCLs interact with chromatin.
JARID2 is the founding member of the Jumonji family of proteins that catalyses the demethylation of histone proteins, yet it lacks the key residues necessary for cofactor binding and is devoid of enzymatic activity. Its deletion in mice results in severe defects in cardiovascular and liver development 25 . The C-terminal half of JARID2 contains some conserved regions such as the ARID domain (a potential DNA-binding domain), the JmjC and JmjN domains, and a zinc finger (Fig. 1) Review insight demonstrated its interaction with EZH2 (refs 22, 26-29) . Genomewide studies showed a large overlap between PRC2 and JARID2 target genes 22, [26] [27] [28] [29] , and the recruitment of JARID2 and PRC2 seems to be partially interdependent. Surprisingly, although PRC2 recruitment is impaired after JARID2 inactivation, H3K27me3 levels are only modestly affected 27, 29 . This observation led to the conclusion that JARID2 is an inhibitor of PRC2 enzymatic activity 26, 27 . However, further characterization of the catalytic activity of PRC2 indicated that JARID2 enhances PRC2 activity under defined biochemical conditions (ref. 22 and J. Son, R.M. and D.R., unpublished data). Furthermore, JARID2 is able to bind to DNA with a slight bias towards (G+C)-rich sequences 22 . This observation correlates with the reported sequence composition of PRC2 target genes 8 , and is consistent with a potential function for JARID2 in PRC2 recruitment.
Studies of these three PRC2 components have given rise to apparent discrepancies. Considering that the factors are not strictly required for PRC2 enzymatic activity in vitro, it is perhaps unsurprising that their inactivation would result in milder consequences than the inactivation of a core PRC2 component. Nonetheless, these factors are necessary for optimum PRC2 activity, and the regulation of PRC2 recruitment and its enzymatic activity are tightly connected. We propose that PRC2 functions as a holoenzyme ( Fig. 1) , with the additive contribution of each of its components being required for maximum activity.
H3K27 methylation
It remains to be determined whether the composition of PRC2 is modified as a consequence of, or during the processes of, tumorigenesis, development and/or maintenance of adult tissue specificity. Thus far, despite the different proteins found associated with the core complex, its integrity remains intact such that all PRC2 complexes containing either EZH1 or EZH2 catalyse H3K27 methylation. Lysine can be mono-, dior trimethylated, with each methylation level likely to be functionally distinct. Methylation of H3K27 is processive (H3K27me3 results from monomethylation of H3K27me2), and H3K27me3 is a stable mark 30 . Methylated H3K27 is very abundant, with roughly 50% of the H3 histone being dimethylated, 15% trimethylated and 15% monomethylated in embryonic stem (ES) cells 31 . Although the Pc component of PRC1 binds to H3K27me2 and -me3 through its chromodomain in vitro, it seems specific for H3K27me3 in vivo, and H3K27me2 seems to be of limited importance for maintenance of gene repression 23 . We previously proposed that H3K27me2 is an important intermediary PRC2 product, because it not only constitutes the substrate for subsequent H3K27me3 formation, but might also prevent H3K27 from being acetylated. Acetylated H3K27 is thought to be antagonistic to PcGmediated silencing and is enriched in the absence of PRC2 (ref. 32) .
With the exception of a viral protein, PRC2 has the only enzymatic activity found thus far that both di-and trimethylates H3K27. These methyl marks are associated with facultative heterochromatin -a subdivision of heterochromatin that is regulated in a developmentalspecific manner 33 . The monomethylated version of H3K27 is associated with constitutive heterochromatin -a more stably silent, gene-poor region of chromatin -but its enrichment through the gene body is correlated with actively transcribed genes 34 . Exactly how H3K27me1 arises is still controversial. In plants, H3K27 is monomethylated by two enzymes, ATXR5 and ATXR6, which are distinct from PRC2 and not conserved in mammals 35 . But H3K27me1 in mammals is still detected in cells bearing non-functional PRC2 (refs 10, 36) . We speculate that in mammals, H3K27me1 is placed by an enzymatic activity distinct from that of PRC2, and that the presence of H3K27me1 in actively transcribed genes could arise from the demethylation of H3K27me2/3 by the demethylases UTX or JMJD3 (ref. 37) . Whether these demethylases can function on H3K27me1 in vivo is an open question.
In general, histone PTMs regulate biological processes either by altering chromatin structure (by loosening the DNA-histone interaction) or by contributing to the recruitment of further regulatory factors. Thus far, H3K27me3 has been implicated in only the latter mechanism of action, suggesting that other factors such as PRC1 are required to maintain gene repression. H3K27me3 might also indirectly regulate transcription by sterically preventing proteins from binding to chromatin. Enrichment of H3K27me3 correlates with gene silencing 38 , and this observation is supported by the finding that H3K27me3 and H3K36me3, a mark that is linked to transcription elongation, have distinct localizations 39 . RNA polymerase (Pol) II that is phosphorylated at Ser 5 of its C-terminal domain is present in a substantial fraction of H3K27me3-enriched promoters 40 , and low transcript levels are detected 41 , leading to the suggestion that RNA Pol II could be paused at PcG-targeted genes 40 . Indeed, several PcGregulated genes in Drosophila and mammals can recruit the RNA Pol II transcription complex to their respective promoters and engage in early transcription, yet these polymerases encounter an early block to elongation. A recent study indicates that short transcripts that are generated after transcription and remain bound to a paused RNA Pol II could recruit PRC2 (ref. 42 ). If confirmed, this suggests that PRC2 and H3K27me3 can affect gene expression by controlling an 
engaged RNA Pol II during promoter escape or elongation, rather than by regulating the initiation phase of transcription. A likely possibility is that PRC2 can repress transcription by different mechanisms, and this may be gene specific.
Genome-wide localization of PRC2 and H3K27me3
Several publications have reported the genome-wide localization of H3K27me3 in various cell lines and organisms, with some divergent results depending on the methodology used and the model analysed. A conservative estimation is that PRC2 targets represent at least 10% of the genes in ES cells 43 . PRC2 specifically resides at -and targets for H3K27me3 deposition -the Hox genes and numerous genes encoding other developmental regulators [44] [45] [46] . Interestingly, in human cancer cells, the PRC2 component SUZ12 is mainly enriched at the promoters of genes encoding glycoprotein and immunoglobulin-like proteins 47 . Further studies are required to determine whether this is a consequence of the genetic and epigenetic alterations of cancer cells or whether it is a reflection of the cancer-cell origin.
In Drosophila, domains enriched in H3K27me3 were found to cover large regions of the genome, usually exceeding 10 kilobases (kb) 48, 49 . In mammals, two different types of binding pattern have been reported for PRC2 or H3K27me3: some very large domains of more than 100 kb such as those containing the Hox loci, and some smaller domains covering a few kilobases 41, 45, 47, 50 . H3K27me3 enrichment seems to be centred around the transcription start site of promoters, but with a lower intensity at the start site itself 41, 51 (Fig. 2 ). Some H3K27me3 is found at intergenic regions 34, 41 , and H3K27me3 is enriched in subtelomeric regions 52 and in long-terminal repeat retrotransposons 53 . To understand how PRC2 can maintain specific gene-expression patterns, the overall chromatin structure, in addition to H3K27me3 patterns, should be considered 54 . This issue has generated a great deal of attention in the context of ES-cell differentiation (Fig. 2) . ES cells are characterized by a more open and flexible chromatin organization and a higher overall rate of transcription, which is thought to be important for pluripotency 55 . Notably, the H3K4me3 mark, often associated with active transcription, was present at most, if not all, PRC2-targeted genes in ES cells, forming the 'bivalent domain' 39, 41, 43, 51, 56 . Although this pattern was initially believed to be ES-cell specific 56 , bivalent domains have been found in differentiated somatic cells, albeit at a lower frequency 39, 43 ; they were also found in zebrafish 57 but are rarely detected in Drosophila 58 . Another histone species with seemingly disparate functionality that co-localizes with PRC2 is the histone variant H2Az, which is usually associated with active genes (Fig. 2) . Indeed, PRC2 and H2Az co-localize in undifferentiated ES cells, and their recruitment is interdependent 59 . The apparent contradiction in the presence of either H3K4me3 or H2Az with H3K27me3 at the promoters of silent genes in ES cells might reflect the necessary plasticity of these cells, but could also result in partial leakiness of gene silencing. That PRC2 and H2Az co-localize is consistent with the low levels of DNA methylation at PcG target genes in ES cells 60, 61 , given the evolutionarily conserved exclusivity shown by H2Az and DNA methylation 62 . After ES-cell differentiation, a substantial fraction of bivalent domains that lose H3K4me3 and H2Az do gain DNA methylation 43, 60, 61 . Notably, genes enriched in both H3K27me3 and H3K9me3, another mark associated with gene repression, are more abundant in human fetal lung fibroblasts (IMR90) than in human ES cells 50 . In this same study, the authors showed that H3K27me3 domains are more extended in IMR90 cells or CD4 + T cells than in ES cells, and that H3K27me3 domain expansion correlates with more efficient transcriptional silencing 50 . Altogether, these results indicate that somatic cells reinforce gene silencing by increasing the length of H3K27me3 domains and, for a fraction of PRC2-targeted genes, by complementary silencing pathways (H3K27me3 together with H3K9me3 or DNA methylation). Not surprisingly, some pluripotency factors, the expression of which could be deleterious in differentiated cells, are silenced in this redundant fashion 50 .
PRC2 recruitment
Exactly how mammalian PRC2 is recruited to chromatin is not clear. In Drosophila, DNA sequences known as Polycomb response elements (PRE) are targets for PcG protein recruitment when inserted at exogenous loci 3, 6 . Genetic experiments led to the identification of DNA-binding proteins that are required for PcG binding; however, genome-wide analysis showed that any one of these trans-acting factors only partially overlaps with PcG target genes. Instead, it is thought that a combination of these factors might be responsible for the recruitment of PcG proteins.
In mammals, PRC2-targeted sequences are highly enriched in C+G, most of them being classified as CpG islands, but these sequences alone do not indicate a consensus response element 8 . Recently, two publications identified a mammalian PRE on the basis of PcG complex recruitment in Drosophila 9, 63 . Both reports suggested an important role for YY1, the mammalian orthologue of the Drosophila PRE DNA-binding protein PHO, as previously proposed 64 . RYBP, a protein that interacts with both YY1 and PRC1, was shown to be required for PRC1 and PRC2 recruitment 63 . Yet genome-wide analysis in mammals did not show a clear overlap between YY1 and PcG target genes 65 . Moreover, PRC2 is under-represented at YY1 response elements 8 . Hence, so far, there is no strong evidence for the involvement of transcription factors in the recruitment of PRC2 in mammals.
On the other hand, long ncRNAs are becoming recognized as important participants in PRC2 function. In mammals, X-chromosome inactivation initiates the expression of a 17-kb ncRNA, XIST, which coats the X chromosome in cis. Coating with XIST RNA leads to a marked alteration of chromatin structure characterized by a progressive heterochromatinization. The inactive X chromosome becomes methylated at H3K27 in an XIST-dependent manner 66 . The two long stem-loop structures formed by the A repeats present 5ʹ in the XIST RNA interact with PRC2 in vitro 67, 68 , although further regions of XIST are clearly involved because an XIST transcript in which the A repeats are deleted can still recruit PRC2 to the XIST RNA-coated X chromosome 69 . Similarly, the long ncRNA KCNQ1OT1 can mediate PRC2 spreading in cis, thereby maintaining the imprinted expression of the KCNQ1 domain 70 . Long ncRNA could also promote PRC2 binding in trans as shown for the RNA HOTAIR 71, 72 , the expression of which from the HOXC locus is associated with repression of 40 kb of the HOXD locus. Such mechanisms could be common to a large fraction of long ncRNAs 73 . In light of these results, ncRNA seems to be a strong candidate for PRC2 recruitment.
Considering this information, we propose a model in which the sum of relatively weak interactions or low energy steps that are established by each of the PRC2 holoenzyme components would function together to attain the necessary energy to recruit PRC2 (Fig. 3) . This model predicts up to four steps, not necessarily consecutive, that result 
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in the successful recruitment of PRC2: (1) the interaction of JARID2 and AEBP2 with DNA 18, 22 ; (2) the interaction of the histone chaperones RbAp46 or 48 with histones H3 or H4 (ref. 74); (3) the interaction of EED with the product of PRC2 catalysis, H3K27me3 (ref. 75) , and of PCLs with an unknown histone mark; and (4) the interaction of PRC2 components with long ncRNA. The resultant binding specificity could then be modulated by the variation in the composition of the PRC2 holo enzyme and PTMs of its components. Indeed, EZH2 was reported to be phosphorylated at Thr 350 (refs 76, 77) , a modification that modulates PRC2 recruitment 76 . Consistent with the hypothesis that ncRNA will be a major player in the cell-specific recruitment of PRC2, phos phorylation of EZH2(T350) enhances its binding to ncRNA 77 . The large pool of long ncRNA may function, in part, to direct the complex to defined target genes. This targeting may not necessarily entail linear base pairing with target sequences, but instead the tertiary structure of the RNA may be key to specific target gene recognition. In this regard, the global contribution of HOTAIR to PRC2 targeting indicates that ncRNA may also regulate overall PRC2-binding properties to chromatin, either directly or by bridging it to other factors 72 . Hence, ncRNA could regulate the affinity of PRC2 to chromatin in a similar manner to the recently described case of the PRC1 component CBX7 (ref. 78 ). The chromodomain of CBX7 was reported to bind both H3K27me3 and the ncRNA ANRIL (also known as CDKN2B-AS1), and binding to one ligand can modulate the affinity for the other in vitro.
It is not yet clear whether the initial recruitment of PRC2 to a defined gene and the maintenance of its recruitment involve the same mechanisms. The PRC2 component EED can bind H3K27me3, and PRC2 enzymatic activity is stimulated by the presence of H3K27me3, thus generating a positive-feedback loop 75 . The importance of this mechanism is illustrated by the phenotype of Drosophila expressing EED point mutants that prevent its binding to H3K27me3 without altering PRC2 complex formation; this phenotype includes a global reduction in H3K27me2/3. Furthermore, given that some PcG proteins seem to stay bound to chromatin during replication 79 and that the same applies to PRC2 components during mitosis 80 , PRC2 occupancy of chromatin may not necessitate its active recruitment to defined chromatin loci in all cases.
PRC2 pluripotency and differentiation
Two straightforward models could explain the maintenance of stem-cell pluripotency in the context of PRC2-mediated gene repression. Pluripotency is either lost after the expression of developmental regulators that promote differentiation, or lost when the expression of factors requisite for pluripotency are silenced (Fig. 4a) . The first hypothesis is in keeping with the role of PRC2 in maintaining the repression of numerous developmental regulators in ES cells. This led to the suggestion that PRC2 is required for the maintenance of pluripotency 45 . However, later studies reported that ES cells in which a PRC2 component is inactivated could be kept undifferentiated. This finding draws our attention to the second model that posits the requisite repression of pluripotencyspecific factors 16, 36, 81 . Indeed, in mouse ES cells, the inactivation of SUZ12, JARID2 or PCL2 was reported to be associated with an inefficient silencing of the pluripotency factors NANOG and OCT4 (also known as POU5F1) 21, 22, 29 (Fig. 4a) . Furthermore, inactivation of the EZH2 homologue MES-2 extends the plasticity phase during embryonic development in Caenorhabditis elegans 82 . This observation probably results from the failure of the MES-2 mutant to repress genes that should only be expressed during a defined window of time in early development. Altogether, it seems that the sustained expression of pluripotency factors overtakes the aberrant expression of developmental regulators in PRC2-deficient ES cells.
By contrast, when ES cells are induced to differentiate, misregulation of developmental programs becomes more apparent. Hence, although Eed −/− ES cells (formally EED(L196P) but referred to as Eed −/− for simplicity) were unimpaired in their ability to contribute to all tissue lineages in chimaeric embryos 81 , Suz12 −/− ES cells fail to form a proper endodermal layer 36 , and Ezh2 −/− or Eed −/− ES cells display a severe defect in meso endodermal lineage commitment 16 . This phenotype is not restricted to the deletion of PRC2 core components, because impaired differentiation was also reported in Jarid2 −/− and Pcl2-knockdown ES cells [27] [28] [29] . Of note, in contrast to the mild phenotype that results from PRC2 deletion in ES cells, PRC1 inactivation (Ring1a Ring1b double knockout) leads to a proliferation defect, and ES cells cannot be maintained 83 . Furthermore, deletion of the PRC1 component RING1B in the context of Eed −/− ES cells worsens the differentiation defects 53 . These results indicate that PRC1 is not just a downstream effector of PRC2, but instead has distinct functions, and its recruitment is at least partially PRC2 independent.
On the basis of the example of ES-cell differentiation, we would expect PRC2 inactivation to prevent lineage commitment and terminal differentiation. Although PRC2 defects do prevent adipogenesis and lymphopoiesis 84, 85 , PRC2 inactivation also promotes differentiation during myogenesis and epidermis formation 86, 87 (Fig. 4b) . During B-cell maturation, EZH2 is required for V H J558 gene rearrangement, and the transition from pro-B to pre-B cells is altered in its absence 84 . In the case of epidermis, PRC2 inactivation leads to upregulation of epidermal genes mediated by the transcription factor AP1. Those genes are normally expressed at the late stage of differentiation 87 . Considering that only a small subset of its target genes is reactivated after PRC2 inactivation, it is likely that individual functions encoded by these genes dictate the global consequences for cell differentiation. 
PRC2 and cancer
The expression of PRC2 components is upregulated in various cancers such as melanoma, lymphoma, and breast and prostate cancer. EZH2 has been reported to be a marker of the aggressive stages of prostate and breast malignancies 88, 89 , and its overexpression promotes neoplastic transformation of normal prostatic cells 90 and hyperplasia in breast epithelium 89, 91 . With the exception of the EZH1 homologue, the expression of PRC2 components is regulated by the retinoblastoma protein (pRB)-E2F transcription factors pathway, and is therefore associated with cell proliferation 14, 92 . In addition, several microRNAs control EZH2 expression, the deregulation of which could contribute to EZH2 overexpression in cancer. Deletion of PRC2 components in somatic cells led to a marked reduction in cell proliferation 88, 92 , an effect that was linked to the PRC2-dependent regulation of the Ink4/Arf locus (also known as the Cdkn2a locus), which encodes the tumour-suppressor proteins p16
Ink4a
, p19
Arf and p15 Ink4b (refs 87, 93) . Given these findings, EZH2 was proposed to function as an oncogene 92 . Recurrent somatic mutations that interfere with EZH2 enzymatic activity occur in subtypes of lymphoma 94 and myeloid disorder 95, 96 , but further studies are required to determine the consequences of these deletions for PRC2 activity. Despite the above-mentioned results, EZH2 inactivation does not inhibit cell proliferation in all model cell lines for prostate cancer 97 .
To understand the role of PRC2 in tumour progression, it may be more beneficial to determine whether PRC2 is required for the de-differentiation of somatic cells or for the epithelial to mesenchymal transition, rather than modulating EZH2 levels to gauge its function as a tumour-suppressor protein versus an oncoprotein in a defined cell context. Indeed, the apparent outcome in the latter case is probably dependent on the genetic and epigenetic alterations that initiate cellular transformation. Notably, PRC2 seems to be required for the acquisition of pluripotency, as Eed −/− and Suz12 −/− ES cells fail to induce the reprogramming of B cells in a heterokaryon assay 98 . If similar mechanisms operate during the reprogramming of somatic cells and during tumour progression, we would expect EZH2 inhibition to be a good approach towards preventing the transition to advanced stages of cancer. Yet, if the carcinogenic process initiates from cancer stem cells, it will be crucial to attain a better understanding of how PRC2 modulates proliferation and, in particular, why PRC2 deletion inhibits the proliferation of some somatic cells but not ES cells.
Perspective
The progress made in understanding the role of PcG proteins, and especially PRC2, has underscored their versatility. Not only is PRC2 involved in the regulation of a broad array of biological processes, but it also establishes regulatory cues that are stable and propagated throughout development. These cues can be subject to adjustment at every step of differentiation or in response to external stimuli. With such a pivotal role in maintaining the repression of different sets of genes depending on the cell type and the developmental stage, PRC2 must be targeted to chromatin by a coordinated and intricate process, the steps of which may entail specific DNA sequence(s), ncRNAs and the chromatin structure associated with its target genes. However, this model relies on hypotheses that require validation. Such validation entails clarification of how ncRNA can recognize defined genomic locations and the exact mechanism by which JARID2 or PCL proteins contribute to PRC2 recruitment.
Although it has now been clearly established that several components of PRC2 are misregulated in disease, their involvement has not been well defined yet. Mouse models that allow genetic manipulations, in conjunction with direct comparisons at the genome-wide level of normal versus pathogenic tissues in defined genetic backgrounds, may provide solid resources for pinpointing the parameters of PRC2-dictated processes. ■
